Search

Your search keyword '"Burra, P. (Patrizia)"' showing total 3 results
Start Over Author "Burra, P. (Patrizia)"
3 results on '"Burra, P. (Patrizia)"'

1. Recent advances in alcohol-related liver disease (ALD): summary of a Gut roundtable meeting

Author

Avila, M.A. (Matías Antonio), Dufour, J.F. (Jean-Francois), Gerbes, A. (Alexander), Zoulim, F. (Fabien), Bataller, R. (Ramón), Burra, P. (Patrizia), Cortez-Pinto, H. (Helena), Gao, B. (Bin), Gilmore, I. (Ian), Mathurin, P. (Philippe), Moreno, C. (Christophe), Poznyak, V. (Vladimir), Schnabl, B. (Bernd), Szabo, G. (Gyongyi), Thiele, M. (Maja), and Thursz, M.R. (Mark R.)

Subjects
Alcohol use disorder, Alcohol-related liver disease, Steatosis, Cirrhosis, The gut-liver axis, Acute on chronic liver failure, Alcohol consumption, Alcoholic hepatitis, Fibrosis, Liver transplant, Animal modelsTherapeutic targets
Abstract

Alcohol-related liver disease (ALD), which includes a range of disorders of different severity and is one of the most prevalent types of liver disease worldwide, has recently regained increased attention. Among other reasons, the realisation that any alcohol intake, regardless of type of beverage represents a health risk, and the new therapeutic strategies tested in recently published or undergoing clinical trials spur scientific interest in this area. In April 2019, Gut convened a round table panel of experts during the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) in Vienna to discuss critical and up-to-date issues and clinical trial data regarding ALD, its epidemiology, diagnosis, management, pathomechanisms, possible future treatments and prevention. This paper summarises the discussion and its conclusions.

Published
2020

2. Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis

Author

Beckebaum, S., Herzer, K. (Kerstin), Bauhofer, A. (Artur), Gelson, W. (William), De Simone, P. (Paolo), Man, R.A. (Robert) de, Engelmann, C. (Cornelius), Müllhaupt, B. (Beat), Vionnet, J. (Julien), Salizzoni, M. (Mauro), Volpes, R. (Riccardo), Ercolani, G. (Giorgio), Carlis, L. (Luciano) de, Angeli, V., Burra, P. (Patrizia), Dufour, J.-F. (Jean-François), Rossi, M. (Massimo), Cillo, U. (Umberto), Neumann, U., Fischer, L. (Lutz), Niemann, G. (Gabriele), Toti, L. (Luca), Tisone, G. (Guiseppe), Beckebaum, S., Herzer, K. (Kerstin), Bauhofer, A. (Artur), Gelson, W. (William), De Simone, P. (Paolo), Man, R.A. (Robert) de, Engelmann, C. (Cornelius), Müllhaupt, B. (Beat), Vionnet, J. (Julien), Salizzoni, M. (Mauro), Volpes, R. (Riccardo), Ercolani, G. (Giorgio), Carlis, L. (Luciano) de, Angeli, V., Burra, P. (Patrizia), Dufour, J.-F. (Jean-François), Rossi, M. (Massimo), Cillo, U. (Umberto), Neumann, U., Fischer, L. (Lutz), Niemann, G. (Gabriele), Toti, L. (Luca), and Tisone, G. (Guiseppe)

Abstract

BACKGROUND Long-term real-world data are relatively sparse regarding recurrence of chronic hepatitis B virus (HBV) infection after liver transplantation using hepatitis B immunoglobulin (HBIg) and nucleos(t)ide analogue (NUC) prophylaxis. MATERIAL AND METHODS Data from 371 adults transplanted for HBV-related disease at 20 European centers and given HBIg for ³12 months ± NUC therapy were analyzed retrospectively. RESULTS HBIg comprised Hepatect® (iv HBIgB; n=299), subcutaneous Zutectra® (sc HBIg, n=236), and other HBIg preparations (n=130); 93.5% received NUC therapy. Mean follow-up was 6.8±3.5 years. The primary efficacy variable, freedom from HBV recurrence, occurred in 95.7% of patients (95% CI [93.1%, 97.5%]). The observed incidence of recurrence was 16/371 (4.3%) (annual rate 0.65%); 5/16 patients with recurrence had discontinued HBIg and 7/16 had anti-HBs <100 IU/l. Excluding these 7 patients, the HBV recurrence rate was 2.4%. The recurrence rate while on HBIg therapy was 1 per 2069 months. In patients who discontinued HBIg, risk of HBV recurrence versus sc HBIg users was increased by 5.2-fold (1 per 1 603 versus 1 per 8379 treatment months). The annual rate of HBV-related hepatocellular carcinoma (HCC) recurrence was 1.7%. CONCLUSIONS These results support the long-term use of HBIg with NUC therapy as an effective management strategy to minimize risk of HBV recurrence and virus-related complications after liver transplantation.

Published
2018
Full Text
View/download PDF

3. Primary liver transplantation for autoimmune hepatitis: A comparative analysis of the European liver transplant registry

Author

Schramm, C. (Christoph), Bubenheim, M. (Michael), Adam, R. (René), Karam, V. (Vincent), Buckels, J. (John), O'Grady, J.G. (John), Jamieson, N. (Neville), Pollard, S. (Stephen), Neuhaus, P. (Peter), Manns, M.M. (Michael), Porte, R.J. (Robert), Castaing, D. (Denis), Paul, A. (Anna), Traynor, O. (Oscar), Garden, J. (James), Friman, S. (Styrbjörn), Ericzon, B.G., Fischer, L. (Lutz), Vitko, S. (Stefan), Krawczyk, M. (Marek), Metselaar, H.J. (Herold), Foss, A. (Aksel), Kilic, M. (Murat), Rolles, K. (Keith), Burra, P. (Patrizia), Rogiers, X. (Xavier), Lohse, A.W. (Ansgar), Schramm, C. (Christoph), Bubenheim, M. (Michael), Adam, R. (René), Karam, V. (Vincent), Buckels, J. (John), O'Grady, J.G. (John), Jamieson, N. (Neville), Pollard, S. (Stephen), Neuhaus, P. (Peter), Manns, M.M. (Michael), Porte, R.J. (Robert), Castaing, D. (Denis), Paul, A. (Anna), Traynor, O. (Oscar), Garden, J. (James), Friman, S. (Styrbjörn), Ericzon, B.G., Fischer, L. (Lutz), Vitko, S. (Stefan), Krawczyk, M. (Marek), Metselaar, H.J. (Herold), Foss, A. (Aksel), Kilic, M. (Murat), Rolles, K. (Keith), Burra, P. (Patrizia), Rogiers, X. (Xavier), and Lohse, A.W. (Ansgar)

Abstract

The principal aim of this study was to compare the probability of and potential risk factors for death and graft loss after primary adult and pediatric liver transplantation in patients undergoing transplantation for autoimmune hepatitis (AIH) to those in patients undergoing transplantation for primary biliary cirrhosis (PBC; used as the reference group) or alcoholic cirrhosis (used as an example of a nonautoimmune liver disease). The 5-year survival of patients undergoing transplantation for AIH (n = 827) was 0.73 [95% confidence interval (CI) = 0.67-0.77]. This was similar to that of patients undergoing transplantation for alcoholic cirrhosis (0.74, 95% CI = 0.72-0.76, n = 6424) but significantly worse than that of patients undergoing transplantation for PBC (0.83, 95% CI = 0.80-0.85, n = 1588). Fatal infectious complications occurred at an increased rate in patients with AIH (hazard ratio = 1.8, P = 0.002 with PBC as the reference). The outcome of pediatric AIH patients was similar to that of adult patients undergoing transplantation up to the age of 50 years. However, the survival of AIH patients undergoing transplantation beyond the age of 50 years (0.61 at 5 years, 95% CI = 0.51-0.70) was significantly reduced in comparison with the survival of young adult AIH patients (0.78 at 18-34 years, 95% CI = 0.70-0.86) and in comparison with the survival of patients of the same age group with PBC or alcoholic cirrhosis. In conclusion, age sign

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results